X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody, designed to selectively block the immune checkpoint VISTA in the tumor microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody, designed to selectively block the immune checkpoint VISTA in the tumor microenvironment, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 addresses the problems by binding only in the low-pH tumor microenvironment.
Lead Product(s): SNS-101
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 addresses the problems by binding only in the low-pH tumor microenvironment.
Lead Product(s): SNS-101
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
SNS-103 is a conditionally active, monoclonal antibody targeting ENTPDase1 (CD39), an enzyme commonly upregulated by tumors and involved in the conversion of ATP into immunosuppressive adenosine in the tumor microenvironment.
Lead Product(s): SNS-103
Therapeutic Area: Oncology Product Name: SNS-103
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
SNS-101 is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 addresses the problems by binding only in the low-pH tumor microenvironment.
Lead Product(s): SNS-101
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Under the terms of the CRADA, Sensei will collaborate with the NCI to expand the development of SNS-101, a conditionally active, pH-selective VISTA-blocking antibody and to assess the mechanism of action of SNS-101 in combination with novel therapeutic modalities.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2023
Details:
The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo® in a Phase 1/2 trial in solid tumors.
Lead Product(s): SNS-101,Cemiplimab
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Details:
SNS-101, a conditionally active antibody targeting the immune checkpoint VISTA, as well as its other TMAb™ (Tumor Microenvironment Activated biologics) platform programs.
Lead Product(s): SNS-101
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
SNS-101 has the potential to unlock VISTA as a powerful immune checkpoint by exploiting the tumor microenvironment using pH-sensitive properties, delivering powerful anti-tumor activity without the negative effects that have thwarted past efforts.
Lead Product(s): SNS-101
Therapeutic Area: Oncology Product Name: SNS-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Washington University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
